More Articles

The case for improving biosimilar regulatory frameworks worldwide Biosimilars/Research | Posted 07/02/2014

In developing countries, where the cost benefits of biosimilar drugs would have the greatest impact, the financial investment needed to develop biosimilars renders them inaccessible. The situation...

Washington State legislation on biosimilars Policies & Legislation | Posted 07/02/2014

Biologicals manufacturers represented by the Biotechnology Industry Association (BIO) and the Washington Biotechnology & Biomedical Association have welcomed proposed Washington State legislati...

Effects of income, competition and procurement on drug prices in emerging markets Generics/Research | Posted 07/02/2014

Drugs are least affordable relative to income in low-income countries, according to an analysis of income, competition and procurement on drug prices in emerging markets [1].

Mylan launches trastuzumab ‘similar biologic’ in India Biosimilars/News | Posted 07/02/2014

Generics giant Mylan announced on 3 February 2014 that its subsidiary, Mylan Pharmaceuticals Private Limited, had launched its trastuzumab ‘similar biologic’ Hertraz to the Indian market.

Forest Labs files lawsuit to stop generic memantine Generics/News | Posted 07/02/2014

Forest Laboratories and Forest Laboratories Holdings (Forest) announced on 31 January 2014 that the company has filed a lawsuit in the US against several generics makers for their generic versions...

Biosimilars: what physicians need to know Reports | Posted 07/02/2014

A biosimilar is a medicinal product that is similar to a biological medicinal product that has already been authorized. Biologicals are comprised of proteins, such as hormones (growth hormones, ins...

Epirus and Ranbaxy sign agreement for infliximab 'similar biologic' Biosimilars/News | Posted 07/02/2014

Epirus Switzerland, a subsidiary of US-based Epirus Biopharmaceuticals, and India-based Ranbaxy Laboratories (Ranbaxy) announced on 9 January 2013 that the two companies had signed a licensing agre...

Improving access to HCV treatment in developing countries Biosimilars/Research | Posted 31/01/2014

Hepatitis C virus (HCV) infection affects 150–180 million people worldwide each year, killing an estimated 350,000. The considerable cost of treatment – US$ 10,000–US$20,000 per patient for a 48-we...